WO2011143229A3 - Lipid compositions and structured lipids containing phospholipids, oral formulations containing the same and methods of making the same - Google Patents

Lipid compositions and structured lipids containing phospholipids, oral formulations containing the same and methods of making the same Download PDF

Info

Publication number
WO2011143229A3
WO2011143229A3 PCT/US2011/035938 US2011035938W WO2011143229A3 WO 2011143229 A3 WO2011143229 A3 WO 2011143229A3 US 2011035938 W US2011035938 W US 2011035938W WO 2011143229 A3 WO2011143229 A3 WO 2011143229A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
methods
oral formulations
lipid compositions
making
Prior art date
Application number
PCT/US2011/035938
Other languages
French (fr)
Other versions
WO2011143229A2 (en
Inventor
John Richardson Palmer
Joseph John Miller
Original Assignee
J3H, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J3H, Inc. filed Critical J3H, Inc.
Publication of WO2011143229A2 publication Critical patent/WO2011143229A2/en
Publication of WO2011143229A3 publication Critical patent/WO2011143229A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Disclosed are lipid compositions and structured lipids containing phospholipids, oral formulations of the same, methods of making the same, and methods of treating various aliments and diseases with the oral formulations. The lipid compositions and structured lipids comprise omega-3 fatty acids, which are present as fatty acids on the R1 and R2 terminal positions of phospholipids. The lipids and methods disclosed herein allow for high purity phospholipid compositions, which aid in the bioavailability of the omega-3 fatty acids. The oral formulations can also contain additional components that further aid in the bioavailability and absorption by the body.
PCT/US2011/035938 2010-05-10 2011-05-10 Lipid compositions and structured lipids containing phospholipids, oral formulations containing the same and methods of making the same WO2011143229A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33317310P 2010-05-10 2010-05-10
US61/333,173 2010-05-10

Publications (2)

Publication Number Publication Date
WO2011143229A2 WO2011143229A2 (en) 2011-11-17
WO2011143229A3 true WO2011143229A3 (en) 2012-03-15

Family

ID=44914944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035938 WO2011143229A2 (en) 2010-05-10 2011-05-10 Lipid compositions and structured lipids containing phospholipids, oral formulations containing the same and methods of making the same

Country Status (1)

Country Link
WO (1) WO2011143229A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069097A1 (en) * 2013-11-08 2015-05-14 N.V. Nutricia Efficacy of dietary dha-phospholipid for brain dha and dpa accretion in neonates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234587A1 (en) * 2001-07-27 2004-11-25 Fotini Sampalis Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
US20060177486A1 (en) * 2004-11-17 2006-08-10 Natural Asa Enzymatically synthesized marine phospholipids
US20090275658A1 (en) * 2004-12-23 2009-11-05 Dirk Fabritius Method for Producing a Raw Oil from Mixtures of Micro-Organisms and Plants, Oil Produced According to Said Method and Specific Uses of the Thus Produced Oil and, Optionally, Additional Refined Oil
US20090297491A1 (en) * 2008-03-20 2009-12-03 Bromley Philip J Compositions containing non-polar compounds
US20100099765A1 (en) * 2007-11-01 2010-04-22 Floyd Chilton Compositions, methods, and kits for polyunsaturated fatty acids from microalgae

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234587A1 (en) * 2001-07-27 2004-11-25 Fotini Sampalis Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
US20060177486A1 (en) * 2004-11-17 2006-08-10 Natural Asa Enzymatically synthesized marine phospholipids
US20090275658A1 (en) * 2004-12-23 2009-11-05 Dirk Fabritius Method for Producing a Raw Oil from Mixtures of Micro-Organisms and Plants, Oil Produced According to Said Method and Specific Uses of the Thus Produced Oil and, Optionally, Additional Refined Oil
US20100099765A1 (en) * 2007-11-01 2010-04-22 Floyd Chilton Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20090297491A1 (en) * 2008-03-20 2009-12-03 Bromley Philip J Compositions containing non-polar compounds

Also Published As

Publication number Publication date
WO2011143229A2 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
MX2015008199A (en) Eicosapentaenoic acid (epa) formulations.
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
MX2022007680A (en) Lipid nanoparticles for delivery of nucleic acids.
CA2868034C (en) Ionizable cationic lipids
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2012170889A8 (en) Cleavable lipids
WO2013068879A3 (en) Infant formula with high sn-2 palmitate and oligofructose
MX2016004487A (en) Enteric soft capsules comprising polyunsaturated fatty acids.
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
GB2459809A (en) Fatty acid formulations and methods of use thereof
CA3009891A1 (en) Lipids, lipid compositions, and methods of using them
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
WO2014057362A3 (en) Omega -3 compositions
MX2013009007A (en) High protein nutritional compositions and methods of making and using same.
NZ596228A (en) Compositions and methods for the treatment of inflammation
MX2014002362A (en) Formulations and dosage forms of oxidized phospholipids.
RU2017129161A (en) LIPID COMPOSITIONS
WO2014039964A3 (en) Compounds and methods for modulating vascular injury
MX2009012782A (en) Formulations for the oral administration of therapeutic agents and related methods.
MX2021015311A (en) Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy.
WO2011121034A3 (en) Water-free pharmaceutical compositions suitable for local anaesthetics
WO2012119781A3 (en) Novel lipids, phospholipids, phospholipid and lipid compositions and their use
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2012171001A3 (en) Food products containing beta-glucans and omega-3 fatty acids
WO2014089511A3 (en) Administering compositions comprising docosapentaenoic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11781150

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A, DATED 27-02-2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11781150

Country of ref document: EP

Kind code of ref document: A2